The latest news from ASH 2024 focused on mantle cell lymphoma (MCL) including abstracts, features, and helpful conference information.
A study at ASH 2024 found that early progression of disease in mantle cell lymphoma significantly worsens survival, indicating the need for a more nuanced approach to risk stratification.
MCL patients with secondary malignancies have significantly shorter survival, particularly due to skin cancers and secondary leukemia.
Luis Sumoza, MD, discusses the BRUIN CLL-321 study presented during the ASH Annual Meeting, highlighting the importance of this research and how it will impact patient care.
A review of treatments for TP53m MCL found high response rates with targeted and CAR-T therapies but highlighted poor survival, urging innovative strategies.
Luis Sumoza, MD, highlights the need to explain the disease, its consequences, and treatment side effects to patients, highlighting effective communication with primary care providers is crucial to ensure coordinated care.
Early palliative care improves transplant patients' quality of life, especially for minoritized groups or those with high distress, suggesting targeted or clinician-led care.
Physician's Weekly spoke with Alexey Danilov, MD, PhD, at ASH 2024 on personalized care and prognostic insights in CLL.
Educational programs and psychological support addressing cancer-related beliefs and promoting healthier coping strategies are crucial for improving outcomes.
According to data from the 66th ASH Annual Meeting, advancements in the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL) have introduced novel therapies such as BTK inhibitors.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
